期刊文献+

乳腺癌相关基因的研究进展 被引量:1

Advances of gene relating to breast cancer
下载PDF
导出
摘要 从 2 0世纪 70年代起 ,原为乳腺癌低发区的亚洲国家发病率逐年升高 ,在我国特别是北京、上海等发达城区已成为危害妇女健康主要恶性肿瘤。乳腺癌病因尚不十分清楚 ,发病机理非常复杂 ,影响乳腺癌发病因素较多。随着分子生物学的飞速发展与各种高新生物技术不断涌现 ,近年来尤为瞩目的基因组学、蛋白质组学、生物信息学、组合化学、生物芯片技术和自动化筛选技术的发展与广泛应用 ,人类基因组计划的初步完成 ,对恶性肿瘤发生、演进机理有了较深入的了解 ,防治水平不断提高。而DNA重组、基因打靶、转基因动物等众多新技术在肿瘤研究中的应用 ,使人们越来越深刻地认识到肿瘤是一种基因的疾病。本文就目前研究较多的HER2、BRCA1从基因定位、结构、执行功能的分子机制及在乳腺癌中的作用等方面进行了总结 ,以便使我们更全面地认识这些基因及其表达产物的生理、病理生理作用 ,为肿瘤防治提供更为全面。
出处 《解剖科学进展》 CAS 2002年第4期377-379,376,共4页 Progress of Anatomical Sciences
  • 相关文献

参考文献18

  • 1Slamon DF, Clark GM, Wong SG, et al. Human breast cancer:correlation of relaose and surivial with amplification of the HER-2/nue oncogene [J]. Science, 1987, 235: 177-182.
  • 2Tzahar E, Pinkas-Kramarski R, Moyer JD, et al. Bivalence of EGF-like ligands drives the ErbB signaling network [J]. EMBO J, 1997, 16: 4938-4950.
  • 3Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands [J]. Biochim Biophys Acta, 1998, 1377: 25-37.
  • 4Dati C, Antonootti S, Taverna D, et al. Inhibition of c-erbB-2 oncogene expression by cstrogens in human breast cancer cells [J]. Oncogene, 1990,5:1001-1006.
  • 5Grunt TW, Saceda M, Martin MB, et al. Bidirectional interactions between the estrogen receptor and the c-erbB-2 singnaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer, 1995, 63:560-567.
  • 6Giani C, Casalini P, Pupa SM, et al. Increased expression of c-erbB-2 in hormon-dependent breast cancer cells inhibits cell growth and; nduces defferentiation [J]. Oncogene, 1998, 17:425-432.
  • 7Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of aduvant tamoxifen in rarly-stage breast cancer with axillary lymph node metastases [J]. J Clin Oncol, 1996,14:2702-4708.
  • 8Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. TheBreast Cancer Linkage Consortium [J]. Am J Hum genet, 1993, 52: 678-701.
  • 9Haile DT, Parvin JD. Activation of transcription in vivte by the BRCA1 carboxy-terminal domain [J]. J Biol Chem, 1999, 274: 2113-2117.
  • 10Hakem R, de la Propa JL, Sirard C, et al. The tumor supperessor gene Brca1 is reguired for embryonic cellular proliferation in the mouse [J]. Cell, 1996, 85:1009.

同被引文献24

  • 1周雪瑞,黄选东.乳腺与乳腺癌[J].生物学通报,2004,39(7):26-27. 被引量:18
  • 2焦德,任国胜.HER 2基因在乳腺癌中的研究进展[J].国外医学(外科学分册),2005,32(5):374-378. 被引量:3
  • 3华彬,韦军民.乳癌HER-2基因研究的进展与现状[J].中国医刊,2006,41(1):46-48. 被引量:5
  • 4Strauss B. Best hope or last hope access to phase Ⅲ clinical trials of HER-2/neu for advanced stage breast cancer patients [ J ], J Advanced Nursing, 2000,31:259-266.
  • 5Normanno N, Ciardiello F. EGF-related peptides in the pathophysiology of the mammary gland [ J ]. J Mammary Gland Biol Neoplasia, 1997,2:143-152.
  • 6Slamon D J, Clark G M, Wong S G, et al. Human breast cancer, correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987,235:177- 181.
  • 7Disis M L, Schiffman K. Cancer vaccines targeting the HER-2/neu oncogenic protein [ J ]. Sem in Oncol, 2001, 28 : 12-20.
  • 8Cell Markers And Cytogenetics Committees College Of American Pathologists. Clinical laboratory assays for HER-2/ neu amplification and overexpression: quality assurance, standardization, and proficiency testing [ J ]. Arch Pathol Lab Med, 2002,126:803-308.
  • 9Arnould L, Denoux Y, Macgrogan G, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer [ J ]. Br J Cancer, 2003,88:1587-1591.
  • 10Ross J S, Fletcher J A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy[ J]. Stem Cells, 1998,16:413-428.

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部